Since epigenetic modifications are reversible, and greater research on developing targeted therapeutics using HDAC inhibitors and DNMT inhibitors may lead to a paradigm shift in the treatment of the subsets of CRS. This evidence concerns the gene DNMT1 and congenital rubella syndrome.